NICE recommends Takhzyro for hereditary angioedema.- Takeda

Takeda announced that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination recommending Takhzyro (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older only if they are eligible for preventive C1-esterase inhibitor (C1-INH) treatment in line with NHS England's commissioning policy, if the lowest dosing frequency of lanadelumab is used in line with the summary of product characteristics and if the company provides lanadelumab according to the commercial arrangement.

Lanadelumab is the first preventative treatment for Type I/II HAE, self-administered by patients at home as a single subcutaneous injection every two to four weeks. In clinical studies, monthly attack rates were reduced by 87% relative to placebo, and patients experienced improvements including less fear and shame about unpredictable attacks, less impairment in their ability to work, socialise, and perform other physical activities and reduced fatigue during the day and a better night's sleep.